Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | CLK1 | P49759 | 5/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.46 |
| ▸ | DAO | P14920 | 3/20 | 0.46 |
| ▸ | BCKDK | O14874 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29742302 | 1.00 | BCL2L1 (0.59) | BCL2L1GPR35TBXAS1CHRNA7HTR3A | |
| SCHEMBL11181835 | 0.91 | BCL2L1 (0.50) | BCL2L1GPR35TBXAS1CHRNA7HTR3A | |
| SCHEMBL3498018 | 0.86 | BCL2L1 (0.53) | BCL2L1GPR35TBXAS1CLK1DYRK1A | |
| SCHEMBL156320 | 0.85 | BCL2L1 (0.59) | BCL2L1GPR35TBXAS1CHRNA7DAO | |
| SCHEMBL17267445 | 0.85 | CHRNA7 (0.46) | BCL2L1CHRNA7HTR3ACLK1DYRK1A | |
| SCHEMBL3402922 | 0.84 | DYRK1A (0.50) | CHRNA7HTR3ACLK1DYRK1ADYRK1B | |
| SCHEMBL4614384 | 0.83 | MEN1 (0.55) | CHRNA7HTR3ACLK1DYRK1ADYRK1B | |
| SCHEMBL15697544 | 0.82 | BCL2L1 (0.53) | BCL2L1GPR35CLK1CLK2 | |
| SCHEMBL657185 | 0.82 | DYRK1A (0.70) | BCL2L1CLK1DYRK1ADYRK1B | |
| SCHEMBL16595549 | 0.81 | CHRNA7 (0.43) | BCL2L1CHRNA7HTR3ACLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273856-B2 | Linear basic compounds having NK-2 antagonist activity and formulations thereof | MENARINI RICERCHE S.P.A. (IT) | 2007-09-25 | — | — | US | claimed |
| EP-1442050-B1 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI SAS (IT) | 2006-09-13 | — | — | EP | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-05 | — | — | US | claimed |
| WO-2002102301-A2 | SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-27 | — | — | WO | claimed |
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-09-12 | — | — | US | claimed |
| CN-114907335-A | 2- (benzothiophene-2-yl) benzo [ d ] oxazole derivative, preparation method and application | 陕西维世诺新材料有限公司 | 2022-08-16 | — | — | CN | disclosed |
| EP-3623371-A1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | Axovant Sciences GmbH (CH) | 2020-03-18 | — | — | EP | disclosed |
| EP-3233087-B1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (DE) | 2019-10-02 | — | — | EP | disclosed |
| EP-3233087-B1 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS | AXOVANT SCIENCES GMBH (DE) | 2019-10-02 | — | — | EP | disclosed |
| US-10183938-B2 | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-01-22 | — | — | US | disclosed |
| US-10183938-B2 | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-01-22 | — | — | US | disclosed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002102301-A2 | SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-09-12 | — | — | US | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| US-4482553-A | ANTIBIOTICS, BACTERICIDES | ELI LILLY AND COMPANY (US) | 1984-11-13 | — | — | US | disclosed |
| EP-0122156-A2 | Improvements in or relating to benzothienylglycyl cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | BCL2L1 29/4885GPR35 1865/4885TBXAS1 1934/4885 |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | BCL2L1 29/4885GPR35 1865/4885TBXAS1 1934/4885 |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | BCL2L1 2632/4885GPR35 674/4885TBXAS1 919/4885 |
| US-10183938-B2 | Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors | CHRNA7, CHRNA6, CHRNA5 | BCL2L1 4824/4885GPR35 59/4885TBXAS1 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.